Continued Research and Development Activities
First written in FY2017-Q1. 26 of 33 entries say "Restated". Latest entry: FY2026.
47 other companies' latest entry also says "Advanced".
- FY2026AdvancedAnnual report
「At the end of the current consolidated fiscal year, the Chemical Industry segment had 65 R&D personnel, and R&D expenses were ¥843 million.」
R&D personnel totaled 65, and R&D expenses were ¥843 million. The company is advancing specific development projects, including new manufacturing processes for resin monomers for optical lenses, chemical recycling, bioplasticizers and scintillator materials. The bioplasticizer received an Industrial Technology Award. - 2026-05-30AdvancedGeneral Meetings of Shareholders
「この度、当該共同研究の成果として、2026年3月27日に、新規有機シンチレーション材料、並びに有機シンチレーションカクテル液の添加剤及び溶媒に関する特許（計6件）を、国立大学法人東海国立大学機構と共同で出願致しました。」
新規有機シンチレーション材料に関する共同研究成果が、計6件の共同特許出願として具体化した。 - FY2026-H1RestatedAnnual report
「The total R&D expenses incurred by the Group during the interim consolidated accounting period were ¥435 million.」
R&D activities are continuing, and R&D expenses for the interim consolidated accounting period were ¥435 million. This was a modest decrease from ¥439 million in the interim period of the previous fiscal year. - FY2025SoftenedAnnual report
「R&D expenses had been budgeted at ¥1 billion per year, but came to approximately ¥800 million due to lower execution of certain expenses and other factors.」
Against the ¥1 billion annual R&D expense target set in the previous medium-term plan, actual spending was approximately ¥800 million, below the planned level. R&D activities themselves are continuing. - FY2025-H1RestatedAnnual report
「The total R&D expenses incurred by the Group during the interim consolidated accounting period were ¥439 million.」
Research and development activities and R&D spending are continuing. R&D expenses for the interim consolidated accounting period were ¥439 million. - FY2024AdvancedAnnual report
「At the end of the current consolidated fiscal year, the Chemical Industry segment had 62 R&D personnel, and R&D expenses were ¥858 million.」
R&D personnel totaled 62, and R&D expenses were ¥858 million. The company is advancing specific development projects, including resin monomers for optical lenses, biomass plasticizers, biodegradable plasticizers and graphene nanoribbons. - FY2024-Q3RestatedAnnual report
「The total R&D expenses incurred by the Group during the nine-month cumulative period of the current consolidated fiscal year were ¥640 million.」
Research and development activities and related expenditure continued. - FY2024-Q2RestatedAnnual report
「The total R&D expenses incurred by the Group during the six-month cumulative period of the current consolidated fiscal year were ¥424 million.」
Research and development activities and related expenditure continued. - FY2024-Q1RestatedAnnual report
「The total R&D expenses incurred by the Group during the three-month cumulative period of the current consolidated fiscal year were ¥204 million.」
Research and development activities and related expenditure continued. - FY2023AdvancedAnnual report
「Regarding new businesses, during the current consolidated fiscal year we established the NEXT Business Development and IP Strategy Department within our research institute, strengthened marketing activities, and promoted new business development leveraging our strengths.」
In addition to continuing R&D, the company established the NEXT Business Development and IP Strategy Department and put in place a specific structure for new business development, including marketing. R&D personnel totaled 59, and R&D expenses were ¥837 million. - FY2023-Q3RestatedAnnual report
「The Group's total research and development expenditure for the nine months ended the third quarter of the fiscal year was ¥630 million.」
Research and development activities and R&D spending are continuing. R&D expenses for the nine-month cumulative period of the current consolidated fiscal year were ¥630 million. - FY2023-Q1RestatedAnnual report
「The Group's total research and development expenditure for the nine months ended the first quarter of the fiscal year was ¥203 million.」
Research and development activities and related expenditure continued. - FY2022RaisedAnnual report
「Research and development expenditure: ¥1 billion per year」
While continuing its research and development activities, the company set a target of ¥1 billion per year for research and development expenditure in its new medium-term management plan. Research and development expenditure for the fiscal year was ¥907 million, and the number of research and development personnel was 58. - FY2022-Q3RestatedAnnual report
「The Group's total research and development expenditure for the nine months ended the third quarter of the fiscal year was ¥672 million.」
Research and development activities and related expenditure continued. - FY2022-Q2RestatedAnnual report
「The Group's total research and development expenditure for the six months ended the second quarter of the fiscal year was ¥446 million.」
Research and development activities and related expenditure continued. - FY2022-Q1RestatedAnnual report
「The Group's total research and development expenditure for the nine months ended the first quarter of the fiscal year was ¥230 million.」
Research and development activities and related expenditure continued. - FY2021RestatedAnnual report
「The Group is actively developing various new products and industrialization processes to respond promptly to changes in markets where international competition is becoming increasingly intense and to diversifying customer needs. As of the end of the fiscal year, it had 58 research and development personnel, and research and development expenditure was ¥783 million.」
The development of new products and industrialization processes continued, with 58 research and development personnel and ¥783 million in research and development expenditure. - FY2021-Q3RestatedAnnual report
「The Group's total research and development expenditure for the nine months ended the third quarter of the fiscal year was ¥574 million.」
Research and development activities and related expenditure continued. - FY2021-Q2RestatedAnnual report
「The Group's total research and development expenditure for the six months ended the second quarter of the fiscal year was ¥385 million.」
Research and development activities and related expenditure continued. - FY2020-Q3RestatedAnnual report
「The Group's total research and development expenditure for the nine months ended the third quarter of the fiscal year was ¥580 million.」
Research and development activities and related expenditure continued. - FY2020-Q2RestatedAnnual report
「The Group's total research and development expenditure for the six months ended the second quarter of the fiscal year was ¥386 million.」
Research and development activities and related expenditure continued. - FY2020-Q1RestatedAnnual report
「The Group's total research and development expenditure for the nine months ended the first quarter of the fiscal year was ¥189 million.」
Research and development activities and related expenditure continued. - FY2019-Q3RestatedAnnual report
「The Group's total research and development expenditure for the nine months ended the third quarter of the fiscal year was ¥594 million.」
Research and development activities and related expenditure continued. - FY2019-Q2RestatedAnnual report
「The Group's total research and development expenditure for the six months ended the second quarter of the fiscal year was ¥402 million.」
Research and development activities and related expenditure continued. - FY2019-Q1RestatedAnnual report
「The Group's total research and development expenditure for the nine months ended the first quarter of the fiscal year was ¥192 million.」
Research and development activities and related expenditure continued. - FY2018RestatedAnnual report
「The Group is actively developing various new products and industrialization processes to respond promptly to changes in markets where international competition is becoming increasingly intense and to diversifying customer needs. As of the end of the fiscal year, it had 52 research and development personnel, and research and development expenditure was ¥719 million.」
The development of new products and industrialization processes continued, with 52 research and development personnel and ¥719 million in research and development expenditure. - FY2018-Q3RestatedAnnual report
「The Group's total research and development expenditure for the nine months ended the third quarter of the fiscal year was ¥538 million.」
Research and development activities and related expenditure continued. - FY2018-Q2RestatedAnnual report
「The Group's total research and development expenditure for the six months ended the second quarter of the fiscal year was ¥366 million.」
Research and development activities and related expenditure continued. - FY2018-Q1RestatedAnnual report
「The Group's total research and development expenditure for the nine months ended the first quarter of the fiscal year was ¥182 million.」
Research and development activities and related expenditure continued. - FY2017RestatedAnnual report
「The Group is actively developing various new products and industrialization processes to respond promptly to changes in markets where international competition is becoming increasingly intense and to diversifying customer needs. As of the end of the fiscal year, it had 53 research and development personnel, and research and development expenditure was ¥711 million.」
Research and development continued, with 53 research and development personnel and ¥711 million in research and development expenditure. Each division worked on new products, process development, performance and quality improvements, and the development of new applications, but no specific commercialization or other achievement was disclosed. - FY2017-Q3RestatedAnnual report
「The Group's total research and development expenditure for the nine months ended the third quarter of the fiscal year was ¥539 million.」
Research and development activities and related expenditure continued. - FY2017-Q2RestatedAnnual report
「The Group's total research and development expenditure for the six months ended the second quarter of the fiscal year was ¥361 million.」
Research and development activities and related expenditure continued. Research and development expenditure was ¥361 million for the six months ended the second quarter of the fiscal year, compared with ¥341 million for the same period of the previous year. - FY2017-Q1First statedAnnual report
「The Group's total research and development expenditure for the nine months ended the first quarter of the fiscal year was ¥184 million.」
Total research and development expenditure for the quarter is disclosed, but no specific research themes or achievement targets are provided.